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Chronic fluoxetine treatment induces lipid accumulation 
 but does not alter the expression of Pref-1 in rat adipose tissue 
This study aims to investigate the effects of chronic fluox-
etine (FLX) treatment on preadipocyte factor-1 (Pref-1) ex-
pression in subcutaneous, visceral and brown adipose tis-
sues, and on the size of vacuoles in adipocytes obtained 
from the perirenal regions in rats. Twenty-eight Wistar rats 
were treated with FLX at two different doses and fourteen 
animals received vehicle. After 40 days of treatment, the 
subcutaneous, perirenal and interscapular adipose tissues 
were collected. Pref-1 expression was examined using an 
immunohistochemical method and the vacuolar area was 
measured in stained sections. In the low dose FLX group, 
the size of vacuoles increased both in male and female ani-
mals. The high dose of FLX also induced a significant in-
crease of vacuole size, but only in male animals. Neither of 
the two doses of FLX has significantly affected the Pref-1 
expression in any type of adipose tissue.
Keywords: fluoxetine, adipose tissue, preadipocyte factor-1, 
vacuole size
 
Major depression is one of the most important psychiatric disorders. Treatment of this 
illness often involves selective serotonin reuptake inhibitors (SSRIs), and a therapeutically 
important drug of this class is fluoxetine (FLX). Although the SSRIs are more or less devoid 
of cardiovascular toxicity, they show other side effects such as metabolic and weight 
changes or endocrine dysfunctions (e.g., sexual disorders) (1). Regarding the metabolic ef-
fect of FLX medication, the initial observations were ambiguous; some evidence sustained 
an anorectic effect (2), others an orectic effect of this drug (3). FLX is currently considered 
to be an anorectic agent, since a large meta-analysis of 257 clinical studies performed by 
Domecq et al. (4) revealed weight loss associated with chronic administration of FLX. 
While the central effects on metabolism, food intake and changes in body mass were 
extensively studied, the peripheral mechanisms underlying these changes remain unclear. 
Pref-1 is an adipokine, which influences the adipocyte function and maturation by inhibit-
ing the differentiation process (5).
LÁSZLÓ-ISTVÁN BÁBA1 
ZSOLT GÁLL2,* 
ISTVÁN LÓRÁNT BÍRÓ1 
TIBOR MEZEI3 
IMRE ZOLTÁN KUN4 
MELINDA KOLCSÁR2
1 County Hospital of Mures 
Tîrgu Mures, Romania
2 Department of Pharmacology  
and Clinical Pharmacy, University  
of Medicine and Pharmacy of Tîrgu 
Mureș, Tîrgu Mureș, Romania
3 Department of Pathology, University 
of Medicine and Pharmacy of Tîrgu 
Mureș, Tîrgu Mureș, Romania
4 Doctoral School, University  
of Medicine and Pharmacy of Tîrgu 
Mureș, Tîrgu Mureș, Romania
Accepted November 27, 2017 
Published online January 25, 2018
* Correspondence; e-mail: gall.zsolt@umftgm.ro
110
L.-I. Baba et al.: Chronic fluoxetine treatment induces lipid accumulation but does not alter the expression of Pref-1 in rat adipose 
tissue, Acta Pharm. 68 (2018) 109–115.
 
The size of lipid vacuoles in adipocytes is an important parameter characterizing 
adipose tissue maturation since these vacuoles are triglyceride depots, the size of which 
reflects the energy storage and maturity of the cells (large vacuole size characterizes ma-
ture adipocytes, while smaller vacuoles can be seen in preadipocytes).
This study was aimed to evaluate the effect of chronic FLX treatment on vacuole size 
and Pref-1 expression in order to identify the peripheral processes of weight gain or loss, 
in which the studied drug may be involved.
EXPERIMENTAL
Chemicals
FLX was donated by Vim Spectrum S.R.L. (Romania) and produced by FIDIA S.p.A., 
Italy. Anti-Dlk/Pref-1 monoclonal antibody was obtained from MBL International Corpo-
ration, USA (clone 24-11).
Animals and experimental design
FLX was administered to 42 adult Wistar rats, divided into 6 groups of 7 animals each 
(6 mg kg–1 bm group, 12 mg kg–1 bm group, and a control group, male and female. Group 
codes used throughout for treated animals were: TM-6, TM-12 for males and TF-6, TF-12 
for females). The animals were provided by the Biobase of the University of Medicine and 
Pharmacy of Tîrgu Mureş, Romania. All experimental procedures were conducted accord-
ing to the institutional and national guidelines for animal experiments, respecting Direc-
tive 2010/63/EU, and have the approval of the Ethics Committee of University of Medicine 
and Pharmacy of Tîrgu Mureş. Food and water were available ad libitum, the light-dark 
cycle was assured by natural light. The animals were held at a temperature of 20 ± 3 °C. 
The drug was administered by oral gavage following a 7-day accommodation period as a 
0.7 % aqueous solution. Control groups received vehicle (distilled water); group codes for 
control animals used throughout: CM for males and CF for females. Considering the half-
life of FLX and of its active metabolite nor-FLX (5 hours and 15 hours, resp.), and high 
bioavailability at high doses (6), the drug was applied in two doses: 6 and 12 mg kg–1, resp., 
once daily at 09:00. At the end of each week, body mass was measured, and the adminis-
tered doses were adjusted according to the change in body mass. After a 40-day trial pe-
riod, the animals were sacrificed by intraperitoneal injection of anesthetics (ketamine 300 
mg kg–1 bm and xylazine 30 mg kg–1 bm, resp.). The perirenal white adipose tissues, inter-
scapular brown tissues and subcutaneous fat tissues were collected. 
Morphometric analysis and immunohistochemistry
Adipose tissue samples were fixed in a 4 % neutral formaldehyde solution and were 
later paraffin-embedded. Approximately 3–5 µm thick sections were deparaffinized by the 
xylene-ethanol sequence. Morphometric analyses of adipocytes consisting of vacuolar ar-
eas from the white perirenal adipose tissue were performed using sections after conven-
tional hematoxyline-eosine staining. Immunohistochemical staining for Pref-1 expression 
was made for all types of adipose tissues, such as white, brown and subcutaneous. Anti-
Dlk/Pref-1 (clone 24-11, MBL, USA) monoclonal antibody was used after a 1:100 dilution. 
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Application of the primary antibody was followed by the two-step peroxidase technique. 
The staining process was performed using diamino-benzidine (DAB) chromogen.
Digital image analysis
Digital slides were made with a Zeiss MiraxScan digital slide acquisition system (Carl 
Zeiss, Germany) mounted with a Marlin F-146C digital camera at a resolution of 1392×1040 
pixels with a Sony ICX267 sensor (Allied Vision Technologies, Germany) through Zeiss 
Plan-Apochromat 20× magnification and 0.8 numerical aperture. The acquisition system 
was controlled by MiraxScan software (3DHistech, Hungary) installed on a Fujitsu-Sie-
mens Celsius Workstation computer (4×2 GHz CPU, 2 GB RAM). For each tissue type, five 
images/specimens were saved from the digital slides both in TIFF and JPG formats. Thus, 
a total number of 300 digital images were prepared for the study. Digital images were not 
altered in any way (contrast, luminosity, levels, etc.) before morphometric analysis. Image 
analysis was carried out using ImageJ software, version 1.44c (Wayne Rasband, National 
Institute of Health, Bethesda, MD, USA). 
After a 7 % contrast enhancement, the images were transformed to 8-bit, black-and-
white (inverted color). After transformation, the cell count was evaluated and vacuolar 
areas were measured for cells with circularity between 0.3 and 1.0, surface area ranging 
from 15 to 12,000 µm2 (Fig. 1a).
Fig. 1. a) The inverted 8-bit black-and-white image of adipose tissue, just before the particle size analysis. 
b) The membrane-linked form of the preadipocyte factor-1 (Pref-1) is located in the proximity of the 
membrane (arrows).
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A color filter was applied to sections (R: 199/255, G: 60/255, B: 0/255). The areas in sec-
tions with the RGB values mentioned were brown colored, thus these were the high Pref-1 
expressing tissue parts. After areas in sections with matching color values were selected, 
the total area was measured. The brown area was then taken as the percent of total area in 
sections (pure area, not counting other structures like capillary). As a result, we calculated 
the percentage of adipose tissue showing high Pref-1 expression since these can be seen as 
brown areas in sections (Fig. 1b).
Statistical analysis
The results were analyzed statistically using Graphpad Prism 5. The vacuolar dimen-
sions and Pref-1 expression were compared between groups using the Kruskal-Wallis test 
and Dunn’s multiple comparison test. The chosen statistical significance level was α = 0.05.
RESULTS AND DISCUSSION
Vacuolar areas of adipocytes from perirenal adipose tissue
Comparing the groups of the same gender, it was found that FLX administration influ-
enced the vacuolar areas significantly (p < 0.001). Male animals treated with the low dose 
(6 mg kg–1) showed a significantly larger vacuolar area compared to the control group of the 
same gender (median: 298.99 µm2 vs. 236.79 µm2, p < 0.0001). A more evident increase was 
observed in the case of males treated with the higher dose (12 mg kg–1). This group showed 
the largest vacuolar area of the three male groups (368.04 µm2, p < 0.0001) (Fig. 2a). This sug-
gests a pro-differentiating effect of FLX at both doses (p < 0.05 in both CM vs. TM-6 and CM 
vs. TM-12). In the case of female animals, the low dose produced a similar increase in area to 
that in males (286.13 µm2 compared to 209.78 µm2 seen in the control group, p < 0.0001) (Fig. 
2b). Interestingly, the female group treated with the high dose had a substantially smaller 
Fig. 2. Vacuolar areas of perirenal adipocytes in: a) male and b) female rats (line: median, boxes: in-
terquartile range, whiskers: 10-90 percentile). CM – control males, TM-6 – males treated with 6 mg 
kg–1 bm FLX, TM-12 – males treated with 12 mg kg–1 bm FLX, CF – control females, TF-6 – females 
treated with 6 mg kg–1 bm FLX, TF-12 – females treated with 12 mg kg–1 bm FLX.
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vacuolar area (185.27 µm2) compared to the female control group (209.78 µm2, p < 0.0001) and 
to the group treated with the low dose of FLX (286.13 µm2, p < 0.0001) (Fig. 2b).
There might be several reasons for the observed differences between the genders. For 
instance, female animals were not ovariectomized nor their estrous cycle was synchro-
nized, and subsequently a hormonal heterogeneity appeared. At the same time, FLX in-
hibited the aromatase enzyme with a key role in estrogen synthesis, consequently disturb-
ing the steroid metabolism (7). Therefore, it might be assumed that the observed results 
were influenced by the heterogeneity of steroid status.
Furthermore, Sun et al. (8) recently evidenced an anti-proliferative and inhibitory ef-
fect of FLX on the adipogenic differentiation in an in vitro model. In that study, lipid ac-
cumulation and PPARγ expression also decreased following FLX treatment. This observa-
tion is in accord with our previous results reporting mass loss tendency and decrease in 
visceral triglyceride content after FLX treatment, especially in female rats (9). Although the 
vacuole area is an important indicator of the adipocyte maturation process, it alone cannot 
characterize adipogenesis.
Pref-1 expression in different adipose tissues
Pref-1 has two forms, soluble and membrane-linked. The latter appears in the proximity 
of the cell membrane after immunostaining, as seen in Fig. 1b.
Fig. 3. The level of Pref-1 expression (percentage areas of sections) in different types of adipose tissues after 
FLX treatment compared to control groups. CM – control males, TM-6 – males treated with 6 mg kg–1 bm 
FLX, TM-12 – males treated with 12 mg kg–1 bm FLX, CF – control females, TF-6 – females treated with 
6 mg kg-1 bm FLX, TF-12 – females treated with 12 mg kg–1 bm FLX. Note: No evaluable results were ob-
tained from the brown interscapular adipose tissue of female animals treated with 6 mg kg–1 bm FLX.
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Analyses of the three types of fat tissue for each animal group showed no correlation 
between FLX administration and Pref-1 expression in any animal group for the three ex-
amined fat tissue types (Fig. 3). The Pref-1 expression level was lower in subcutaneous than 
in perirenal or brown adipose tissue in most of the analyzed sections. However, it must be 
highlighted that untreated males showed a somewhat lower level of Pref-1 expression than 
females. The treatment did not influence Pref-1 expression in female rats. Some male ani-
mals treated with 6 mg kg–1 FLX displayed intense expression of Pref-1, but the difference 
was not significant. It should be noted that dispersion of the data decreased the statistical 
significance of the results.
Explanation of these findings might include several mechanisms involved in the meta-
bolic effects of fluoxetine. Stunes et al. (10) demonstrated that adipocytes have a complete 
functional system for 5-HT synthesis, reuptake and receptor activation. Adipocytes also 
exhibit elevated monoamine oxidase (MAO) levels, metabolizing the free circulating 5-HT 
to its metabolites, 5-hydroxy-indoleacetate and 5-methoxy-indoleacetate (11). Furthermore, 
these metabolites bind to the peroxisome proliferator-activated receptor γ (PPARγ) and 
enhance lipid accumulation in preadipocytes. The PPARγ activation results in altered gene 
expression and a subsequent increase in triglyceride accumulation and preadipocyte dif-
ferentiation (12).
To the best of our knowledge, there is no other data in the literature about the relation 
between Pref-1 expression and FLX treatment in rats. Our study, however, suffers from 
some limitations, such as that, besides Pref-1, there are several other adipokines that gov-
ern the adipose tissue maturation and adipocyte function, which should be taken into 
account as well.
CONCLUSIONS
In conclusion, chronic FLX administration had some important effects on fat tissue 
maturation and adipocyte differentiation: treated male rats displayed increased vacuolar 
areas while female rats treated with the low dose of the drug had increased vacuolar areas 
whereas the high dose slightly lowered the vacuolar area compared to the control group. 
Chronic administration of FLX did not influence Pref-1 expression; a great dispersion of 
values occurred in all three types of fat tissues examined, white visceral (perirenal), white 
subcutaneous and interscapular brown adipose tissues. In light of this study, it can be 
stated that chronic FLX treatment seems to increase the adipocyte vacuolar area under in 
vivo conditions and thus might have a pro-differentiating effect on adipocytes, but it does 
not affect Pref-1 expression in a consistent way. In short, it was found that FLX did not 
exert any peripheral effect related to Pref-1 expression, but it increased the size of lipid 
vacuoles in perirenal adipocytes. To draw more accurate conclusions about the peripheral 
pro- or anti-adipogenic effect of FLX, evaluation of the expression of several other local 
factors is needed, and comparison of in vitro and in vivo data is urged for a deeper under-
standing of the entire phenomenon. 
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